Chagas disease, dengue, leishmaniasis, and 
West Nile virus infection, and helminth infec-
tions; and 
‘‘(B) participate in one or more not-for- 
profit product development partnerships. 
‘‘(b) POLICIES.—A cooperative agreement or grant 
under paragraph (1) shall be entered into or awarded in 
accordance with policies established by the Director of the 
National Institutes of Health or the Health Resources and 
Services Administration, as applicable. 
‘‘(c) COORDINATION WITH OTHER INSTITUTES.— 
The Secretary shall coordinate the activities under this 
section with similar activities conducted by other national 
research institutes, centers, and agencies of the National 
Institutes of Health to the extent that such institutes, cen-
ters, and agencies have responsibilities that are related to 
neglected tropical diseases. 
‘‘(d) USES OF FUNDS.—A cooperative agreement or 
grant under subsection (a) may be used for— 
‘‘(1) staffing, administrative, and other basic 
operating costs, including such patient care costs as 
are required for research; 
‘‘(2) clinical training, including training for al-
lied health professionals, continuing education for 
health professionals and allied health professions 
VerDate Sep 11 2014 
07:22 Apr 17, 2015
Jkt 049200
PO 00000
Frm 00020
Fmt 6652
Sfmt 6201
E:\BILLS\H1797.IH
H1797
SSpencer on DSK4SPTVN1PROD with BILLS
personnel, and information programs for the public 
with respect to neglected tropical diseases; and 
‘‘(3) research and development programs. 
‘‘(e) PERIOD OF SUPPORT; ADDITIONAL PERIODS.— 
‘‘(1) IN GENERAL.—Support of a center of ex-
cellence under this section may be for a period of 
not more than 5 years. 
‘‘(2) EXTENSIONS.—The period specified in 
paragraph (1) may be extended by the Secretary for 
additional periods of not more than 5 years if— 
‘‘(A) the operations of the center of excel-
lence involved have been reviewed by an appro-
priate technical and scientific peer review 
group; and 
‘‘(B) such group has recommended to the 
Secretary that such period should be extended. 
‘‘(f) DEFINITIONS.—In this section: 
‘‘(1) The term ‘neglected tropical disease’ has 
the meaning given to that term in section 5 of the 
End Neglected Tropical Diseases Act. 
‘‘(2) The term ‘product development partner-
ship’ means a partnership to bring together public 
and private sector researchers to develop new, or im-
prove on current, global health tools, such as drugs, 
VerDate Sep 11 2014 
07:22 Apr 17, 2015
Jkt 049200
PO 00000
Frm 00021
Fmt 6652
Sfmt 6201
E:\BILLS\H1797.IH
H1797
SSpencer on DSK4SPTVN1PROD with BILLS
diagnostics, insecticides, vaccines, and vector man-
agement strategies— 
‘‘(A) that are for neglected tropical dis-
eases, including Ebola; and 
‘‘(B) for which there is generally no profit-
able market. 
‘‘(g) AUTHORIZATION
OF
APPROPRIATIONS.—To 
carry out this section, there are authorized to be appro-
priated such sums as may be necessary for each of the 
fiscal years 2016 through 2020.’’. 
SEC. 204. PANEL ON WORM INFECTION SOLUTIONS. 
(a) ESTABLISHMENT.—The Director of the National 
Institutes of Health, in consultation with the Adminis-
trator of the United States Agency for International De-
velopment, shall establish a panel to conduct an evaluation 
of issues relating to worm infections, including potential 
solutions such as deworming medicines (in this section re-
ferred to as the ‘‘panel’’). 
(b) STRATEGIES.—The panel shall develop rec-
ommendations for strategies for solutions with respect 
to— 
(1) repeat infections; 
(2) vector control; 
(3) clean water solutions; 
VerDate Sep 11 2014 
07:22 Apr 17, 2015
Jkt 049200
PO 00000
Frm 00022
Fmt 6652
Sfmt 6201
E:\BILLS\H1797.IH
H1797
SSpencer on DSK4SPTVN1PROD with BILLS
(4) identifying incentives to encourage basic re-
search for less toxic, more effective medicines; and 
(5) improving the success and cost efficiency of 
current programs in these areas, based on a thor-
ough scan of initiatives already underway in both 
the public and private sectors. 
(c) APPOINTMENT OF MEMBERS.—The Director of 
the National Institutes of Health shall appoint as mem-
bers of the panel individuals from the public and private 
sectors who are knowledgeable about or affected by worm 
infections, including— 
(1) at least 2 representatives of nongovern-
mental organizations; 
(2) at least 2 representatives of private industry 
involved in the development of de-worming medica-
tions; 
(3) at least 2 representatives from academia; 
and 
(4) representatives of industries relating to 
sanitation, clean water, and vector control. 
(d) REPORT.—Not later than 1 year after the date 
of the enactment of this Act, the panel shall submit to 
Congress and the Director of the National Institutes of 
Health a report on its findings and recommended strate-
gies, including recommendations for such administrative 
VerDate Sep 11 2014 
07:22 Apr 17, 2015
Jkt 049200
PO 00000
Frm 00023
Fmt 6652
Sfmt 6201
E:\BILLS\H1797.IH
H1797
SSpencer on DSK4SPTVN1PROD with BILLS
action and legislation as the panel determines to be appro-
priate. 
(e) TERMINATION.—The panel shall terminate not 
later than 6 months after submitting the report required 
by subsection (d). 
Æ 
VerDate Sep 11 2014 
07:22 Apr 17, 2015
Jkt 049200
PO 00000
Frm 00024
Fmt 6652
Sfmt 6301
E:\BILLS\H1797.IH
H1797
SSpencer on DSK4SPTVN1PROD with BILLS